Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Tools & Techniques

Using exosomes to switch myeloid cells

Codiak’s exosome therapies against STAT6, CEBPB effectively switch macrophages to kill cancer

Elizabeth S. Eaton, Staff Writer
December 5, 2019 9:06 PM UTC

Driven by the natural biology of exosomes, Codiak has moved beyond diagnostics and targeted cancer therapies to embrace myeloid switching as a strategy to treat cancer.

The biotech presented preclinical data Nov. 18 at the American Association for Cancer Research’s Special Conference on Tumor Immunology and Immunotherapy showing that ASO-carrying exosome therapies can be an effective monotherapy in cancer. ...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Codiak Biosciences Inc.